MCID: ESN004
MIFTS: 44

Eosinophilic Gastritis

Categories: Gastrointestinal diseases, Immune diseases, Rare diseases

Aliases & Classifications for Eosinophilic Gastritis

MalaCards integrated aliases for Eosinophilic Gastritis:

Name: Eosinophilic Gastritis 12 52 15 71
Eosinophilic Enteropathy 52 43 71
Eosinophilic Gastroenteropathy 52
Eosinophilic Gastroenteritis 52
Eosinophilic Esophagitis 52
Eosinophilic Enteritis 52

Classifications:



External Ids:

Disease Ontology 12 DOID:4030
ICD9CM 34 535.7
MeSH 43 C535952
NCIt 49 C27052
SNOMED-CT 67 66329006
UMLS 71 C0267154 C2062326

Summaries for Eosinophilic Gastritis

NIH Rare Diseases : 52 Eosinophilic enteropathy is a condition that causes a type of white blood cell called an eosinophil to build up in the gastrointestinal system and in the blood. Eosinophils play a role in the body's immune response by releasing toxins . Eosinophils are associated with allergic-type reactions, but their specific function is largely unknown. When eosinophils build up in the gastrointestinal tract, this begins to affect the body by causing polyps, tissue break down, inflammation, and ulcers. Eosinophilic enteropathy can occur in children or adults and is characterized by intolerance to some foods. Eosinophilic enteropathy can affect any part of the gastrointestinal tract, and is often named by the part affected: colon (colitis), esophagus (esophagitis), stomach (gastritis), or both the stomach and small intestine (gastroenteritis).

MalaCards based summary : Eosinophilic Gastritis, also known as eosinophilic enteropathy, is related to gastroesophageal reflux and esophageal disease. An important gene associated with Eosinophilic Gastritis is IL5 (Interleukin 5), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Fluticasone and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include small intestine, colon and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Eosinophilic Gastritis

Diseases related to Eosinophilic Gastritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 424)
# Related Disease Score Top Affiliating Genes
1 gastroesophageal reflux 31.3 IL5 CCR3 CCL26 CCL11
2 esophageal disease 31.3 CCL26 ATP4A ATP12A
3 peptic esophagitis 31.2 CCL26 ATP4A ATP12A
4 duodenal obstruction 31.0 ATP4A ATP12A
5 esophageal candidiasis 30.9 CCL26 ATP4A ATP12A
6 hypereosinophilic syndrome, idiopathic 30.9 IL5 FIP1L1
7 intestinal perforation 30.8 ATP4A ATP12A
8 churg-strauss syndrome 30.8 IL5 CCL26 CCL11
9 hernia, hiatus 30.6 ATP4A ATP12A
10 dyskinesia of esophagus 30.6 CCL26 ATP4A ATP12A
11 food allergy 30.5 IL5 IL13 EPX
12 gastroenteritis 30.5 IL5 EPX CCL11
13 pneumatosis cystoides intestinalis 30.5 ATP4A ATP12A
14 polyposis, skin pigmentation, alopecia, and fingernail changes 30.5 ATP4A ATP12A
15 necrotizing gastritis 30.5 ATP4A ATP12A
16 duodenitis 30.5 ATP4A ATP12A
17 aspiration pneumonitis 30.4 ATP4A ATP12A
18 active peptic ulcer disease 30.4 ATP4A ATP12A
19 cytokine deficiency 30.4 IL5 IL13
20 bile reflux 30.4 ATP4A ATP12A
21 drug allergy 30.3 IL5 ATP4A ATP12A
22 gastric dilatation 30.3 ATP4A ATP12A
23 tracheomalacia 30.2 ATP4A ATP12A
24 celiac disease 1 30.2 IL5 IL13 ATP4A ATP12A
25 viral esophagitis 30.2 ATP4A ATP12A
26 volvulus of midgut 30.2 ATP4A ATP12A
27 toxocariasis 30.1 IL5 FIP1L1
28 microscopic colitis 30.1 ATP4A ATP12A
29 gastric lymphoma 30.1 ATP4A ATP12A
30 chronic eosinophilic pneumonia 30.1 IL5 CCL11
31 corneal ulcer 30.0 CCR3 CCL11
32 rhinitis 30.0 IL5 IL13 EPX CCL11
33 granulomatosis with polyangiitis 29.9 IL5 FIP1L1 CCL26
34 lactose intolerance 29.8 ATP4A ATP12A
35 allergic bronchopulmonary aspergillosis 29.6 IL5 EPX CCR3
36 pollen allergy 29.6 IL5 IL13 EPX
37 eosinophilic pneumonia 29.6 IL5 IL13 CCL11
38 proteasome-associated autoinflammatory syndrome 1 29.5 IL5 IL13 CCL11
39 eosinophilic gastroenteritis 29.4 IL5 EPX CCL26 CCL11 ATP4A ATP12A
40 esophagitis 29.2 IL5 IL13 CCR3 CCL26 CCL11
41 intrinsic asthma 29.1 IL5 IL13 CCL24 CCL11
42 bronchitis 28.9 IL5 IL13 CCR3 CCL11
43 allergic rhinitis 28.8 IL5 IL13 EPX CCR3 CCL24 CCL11
44 respiratory allergy 28.5 IL5 IL13 CCR3 CCL24 CCL11
45 allergic asthma 28.5 IL5 IL13 EPX CCL26 CCL24 CCL11
46 dermatitis, atopic 28.0 RNASE2 IL5 IL13 EPX CCR3 CCL26
47 allergic hypersensitivity disease 28.0 IL5 IL13 EPX CCR3 CCL24 CCL11
48 hypereosinophilic syndrome 27.7 IL5 IL13 FIP1L1 EPX CCR3 CCL26
49 asthma 27.2 RNASE2 IL5 IL13 EPX CCR3 CCL26
50 esophagitis, eosinophilic, 1 26.4 SIGLEC8 RNASE2 IL5 IL13 EPX CCR3

Graphical network of the top 20 diseases related to Eosinophilic Gastritis:



Diseases related to Eosinophilic Gastritis

Symptoms & Phenotypes for Eosinophilic Gastritis

GenomeRNAi Phenotypes related to Eosinophilic Gastritis according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 9.55 CCL24
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 9.55 CCL26 EPX
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.55 EPX
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.55 EPX
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 9.55 CCL26
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.55 EPX
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.55 CCL24
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.55 CCL24 CCL26 EPX
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.55 EPX
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 9.55 CCL24
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.55 EPX
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.55 EPX
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 9.55 CCL26
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-94 9.55 CCL24

MGI Mouse Phenotypes related to Eosinophilic Gastritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.76 ATP4A CCL11 CCL24 CCR3 EPX IL13
2 immune system MP:0005387 9.56 ATP4A CCL11 CCL24 CCR3 EPX IL13
3 respiratory system MP:0005388 9.1 CCL11 CCL24 CCR3 IL13 IL5 SIGLEC8

Drugs & Therapeutics for Eosinophilic Gastritis

Drugs for Eosinophilic Gastritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3
Citalopram Approved Phase 4 59729-33-8 2771
4 Soy Bean Phase 4
5 Cromolyn Sodium Phase 4
6 Olive Phase 4
7 Respiratory System Agents Phase 4
8 Anti-Asthmatic Agents Phase 4
9 Bronchodilator Agents Phase 4
10 Dermatologic Agents Phase 4
11 Anti-Inflammatory Agents Phase 4
12 Anti-Allergic Agents Phase 4
13 Gastrointestinal Agents Phase 4
14 Anti-Ulcer Agents Phase 4
15 Antacids Phase 4
16 Proton Pump Inhibitors Phase 4
17 Neurotransmitter Agents Phase 4
18 Autonomic Agents Phase 4
19 Cholinergic Agents Phase 4
20 Psychotropic Drugs Phase 4
21 Serotonin Agents Phase 4
22 Serotonin Uptake Inhibitors Phase 4
23 Antiparkinson Agents Phase 4
24 Muscarinic Antagonists Phase 4
25 Cholinergic Antagonists Phase 4
26 Antidepressive Agents Phase 4
27 Parasympatholytics Phase 4
28
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
29 Reslizumab Approved, Investigational Phase 2, Phase 3
30
Esomeprazole Approved, Investigational Phase 2, Phase 3 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
31 Benralizumab Approved, Investigational Phase 2, Phase 3 1044511-01-4
32
Histamine Approved, Investigational Phase 3 51-45-6 774
33
Ketotifen Approved Phase 3 34580-13-7, 34580-14-8 3827
34 Antibodies, Monoclonal Phase 3
35 Immunoglobulins Phase 3
36 Antibodies Phase 3
37 Immunologic Factors Phase 3
38 Antipruritics Phase 3
39
Histamine Phosphate Phase 3 51-74-1 65513
40 Histamine H1 Antagonists Phase 3
41 Histamine Antagonists Phase 3
42
Omalizumab Approved, Investigational Phase 2 242138-07-4
43
Infliximab Approved Phase 2 170277-31-3
44
Budesonide Approved Phase 2 51333-22-3 63006 5281004
45
tannic acid Approved Phase 2 1401-55-4
46
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
47
Losartan Approved Phase 2 114798-26-4 3961
48
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198
49
Bethanechol Approved Phase 2 674-38-4 2370
50
mometasone furoate Approved, Investigational, Vet_approved Phase 2 83919-23-7

Interventional clinical trials:

(show top 50) (show all 153)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled Study of the Use of Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Completed NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
3 COMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS) Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
4 Randomized Controlled Trial Comparing Fluticasone Plus Omeprazole With Fluticasone Alone for Eosinophilic Esophagitis Recruiting NCT03781596 Phase 4 Fluticasone;Omeprazole;Placebo oral capsule
5 Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE) Not yet recruiting NCT04149470 Phase 4 Omeprazole 20mg BID
6 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
7 Proton Pump Inhibitor (PPI's) and Selective Serotonin Reuptake Inhibitor Therapy (SSRI's) for the Management of Non Cardiac Chest Pain (NCCP) Terminated NCT02825342 Phase 4 Citalopram
8 Effect of Swallowed Fluticasone Propionate on Eosinophilic Esophagitis; A Prospective, Randomized, Placebo-Controlled Trial Completed NCT00266578 Phase 3 Fluticasone Propionate
9 An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
10 Double-blind, Randomized, Placebo-controlled, Phase III Trial on the Efficacy and Tolerability of a 6-week Treatment With Budesonide Effervescent Tablets vs. Placebo for Induction of Clinico-pathological Remission in Adult Patients With Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3 Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
11 Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study Completed NCT02605837 Phase 3 Oral Budesonide Suspension (OBS);Placebo
12 An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002 Completed NCT00635089 Phase 3 reslizumab
13 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3 Esomeprazole;Budesonide
14 Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Completed NCT02610816 Phase 2, Phase 3 Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
15 Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial Completed NCT02778867 Phase 2, Phase 3 Flovent
16 A Double-Blind, Placebo-controlled Clinical Trial to Evaluate Efficacy of Benralizumab in Subjects With Eosinophilic Gastritis Recruiting NCT03473977 Phase 2, Phase 3
17 A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03245840 Phase 3 Budesonide oral suspension
18 A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Recruiting NCT03633617 Phase 3 Dupilumab;Placebo
19 Double-blind, Placebo-controlled, Cross-over Trial of Ketotifen in Children and Adolescents With Functional Dyspepsia in Association With Duodenal Eosinophilia Recruiting NCT02484248 Phase 3 Ketotifen;Placebo
20 Double-blind, Randomized, Placebo-controlled, Phase III Study on the Efficacy and Tolerability of a 48-week Treatment With Two Different Doses of Budesonide Effervescent Tablets vs. Placebo for Maintenance of Clinico-pathological Remission in Adult Patients With Eosinophilic Esophagitis Active, not recruiting NCT02493335 Phase 3 Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
21 A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT02736409 Phase 3 Oral Budesonide Suspension (OBS);Placebo
22 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Withdrawn NCT01702701 Phase 3 Montelukast;Fluticasone
23 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Completed NCT03496571 Phase 2 AK002
24 A Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic Esophagitis Completed NCT00426283 Phase 2 Flovent
25 Pilot Study of Omalizumab in Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2 Omalizumab
26 A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis Completed NCT02098473 Phase 2 RPC4046;Placebo
27 A Double Blinded Randomized Placebo-controlled Trial of Intravenous QAX576 in the Treatment of Eosinophilic Esophagitis (EoE) Completed NCT01022970 Phase 2 QAX576 placebo;QAX576
28 A Randomized, Placebo-controlled, Double-blind, Single-centre Proof-of-concept Study of OC000459 in Adult Patients With Active Eosinophilic Esophagitis Completed NCT01056783 Phase 2 OC000459;Placebo
29 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial Completed NCT00638456 Phase 2 Budesonide plus Prevacid;placebo plus Prevacid
30 Oral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and Adolescents Completed NCT00762073 Phase 2 budesonide;placebo
31 A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children Completed NCT02579876 Phase 2 Viaskin Milk 500 mcg;Viaskin Placebo
32 A Randomized, Double-blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219) Completed NCT00358449 Phase 2 mepolizumab
33 Double-blind, Double-dummy, Randomized, Placebo-controlled, Phase IIa Study on the Efficacy and Tolerability of a 14-day Treatment With Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Patients With Eosinophilic Esophagitis Completed NCT02280616 Phase 2 low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo
34 Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension Completed NCT01642212 Phase 2 Oral Budesonide Suspension (MB-9);Placebo
35 A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis Completed NCT02379052 Phase 2 Dupilumab;Placebo
36 Budesonide for Eosinophilic Esophagitis: a Randomized, Placebo-controlled, Double-blind Treatment Study Completed NCT00271349 Phase 2 Budesonide
37 A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Subjects With Eosinophilic Esophagitis (EoE) Completed NCT01386112 Phase 1, Phase 2 EUR-1100;placebo
38 A Randomized Placebo-controlled Trial of Swallowed Fluticasone in Treatment of Eosinophilic Esophagitis Completed NCT00275561 Phase 2 Fluticasone;Placebo
39 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2 esomeprazole;fluticasone
40 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2 omalizumab;Placebo
41 Phase 2 Proof-of-Concept Study to Analyze the Efficacy of in TNF-Alpha Blockade in Adult Patients With Severe, Corticosteroid-Dependent Eosinophilic Esophagitis Completed NCT00523354 Phase 2 Infliximab
42 A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
43 A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary Evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous Anti-human Interleukin-5 (Mepolizumab, 750mg and 1500mg) in the Treatment of Eosinophilic Oesophagitis in Adults Completed NCT00274703 Phase 2 mepolizumab
44 Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid. Completed NCT01705795 Phase 2 Mepolizumab (a-IL-5 antibody);Placebo
45 A Pilot Phase II Study of the Efficacy of Humanized Anti-IL5 Antibody (SCH55700) in Reducing Eosinophilia in Patients With Hypereosinophilic Syndrome or Eosinophilic Gastroenteritis Refractory to or Intolerant of Conventional Therapy Completed NCT00017862 Phase 2 SCH55700
46 A Multi-center, Randomized, Double Blind, Parallel-arm, Placebo Controlled Trial of Mepolizumab for Treatment of Adults and Adolescents With Active Eosinophilic Esophagitis and Dysphagia-predominant Symptoms Recruiting NCT03656380 Phase 2 Mepolizumab 300 mg;Mepolizumab 100 mg
47 Prospective Evaluation of the Clinical Utility of Budesonide for the Prevention of Esophageal Strictures After Endotherapy Recruiting NCT02069847 Phase 2 Budesonide
48 A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder Active, not recruiting NCT03029091 Phase 2 Losartan Potassium
49 A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder. Active, not recruiting NCT01808196 Phase 2 Losartan Potassium
50 FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis Active, not recruiting NCT03191864 Phase 2 APT-1011;Placebo

Search NIH Clinical Center for Eosinophilic Gastritis

Cochrane evidence based reviews: eosinophilic enteropathy

Genetic Tests for Eosinophilic Gastritis

Anatomical Context for Eosinophilic Gastritis

MalaCards organs/tissues related to Eosinophilic Gastritis:

40
Small Intestine, Colon, Testes, T Cells, Bone, Skin, Lung

Publications for Eosinophilic Gastritis

Articles related to Eosinophilic Gastritis:

(show top 50) (show all 118)
# Title Authors PMID Year
1
Ascites in a young male: idiopathic FIP1L1-PDGFRA-negative hypereosinophilic syndrome. 61
32002188 2020
2
Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: Multi-site study. 61
31738990 2020
3
Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders. 61
31773359 2019
4
Eosinophilic Gastrointestinal Disorders. 61
30903439 2019
5
Eosinophilic Gastrointestinal Diseases in Children: A Practical Review 61
31642786 2019
6
[Severe Upper Gastrointestinal Bleeding due to Ulcerative Eosinophilic Gastritis in a 79-Year-Old Man]. 61
31252443 2019
7
Severe anaemia after gastric biopsy in an infant with eosinophilic gastritis. 61
31171002 2019
8
Increasing Rates of Diagnosis, Substantial Co-Occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis, and Colitis Based on 10-Year Data Across a Multicenter Consortium. 61
31008735 2019
9
Severe upper gastrointestinal bleeding due to eosinophilic gastritis. 61
30017211 2019
10
Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis. 61
29940308 2018
11
Impact on Health-Related Quality of Life in Adults with Eosinophilic Gastritis and Gastroenteritis: A Qualitative Assessment. 61
29476289 2018
12
Eosinophilic gastritis with involvement of esophageal gastric inlet patch. 61
29108982 2018
13
[Epidemiological, clinical and diagnostic characterization of children with eosinophilic gastroenteropathy. A retrospective study of three high complexity health institutions]. 61
29983012 2018
14
Eosinophilic Gastrointestinal Diseases in Childhood. 61
30783041 2018
15
Gene Expression Patterns in Distinct Endoscopic Findings for Eosinophilic Gastritis in Children. 61
28526277 2017
16
Pyloric obstruction due to massive eosinophilic infiltration in a young adult dog. 61
29089651 2017
17
Eosinophilic Enteropathy Presenting as Small Bowel Obstruction. 61
30454227 2017
18
Hypereosinophilic Syndrome With Eosinophilic Gastritis. 61
28491930 2017
19
Eosinophilic Gastrointestinal Disorders Pathology. 61
29379785 2017
20
Oral and Sublingual Immunotherapy: Potential Causes for Eosinophilic Gastrointestinal Disorders? 61
28226319 2017
21
Eosinophilic gastroenteritis: A state-of-the-art review. 61
27253425 2017
22
Simultaneous or sequential gastrectomy in pediatric liver transplant recipients. 61
27412691 2016
23
[Eosinophilic gastritis as an evanescent gastric tumor]. 61
27569175 2016
24
Eosinophilic gastrointestinal disorders associated with autoimmune connective tissue disease. 61
26709253 2016
25
Pharmacological treatment of eosinophilic gastrointestinal disorders. 61
27191032 2016
26
[Eosinophilic gastrointestinal disorders]. 61
28675283 2016
27
Primary Eosinophilic Gastritis in a Child with Gastric Outlet Obstruction. 61
26768007 2016
28
Ileoileal Intussusceptions Caused by Eosinophilic Enteropathy. 61
25000350 2016
29
[Contact allergic gastritis : Rare manifestation of a metal allergy]. 61
26909810 2016
30
Prevalence of Eosinophilic Gastritis, Gastroenteritis, and Colitis: Estimates From a National Administrative Database. 61
25988554 2016
31
Wheat allergy: diagnosis and management. 61
26889090 2016
32
Autoimmune Metaplastic Atrophic Gastritis: Recognizing Precursor Lesions for Appropriate Patient Evaluation. 61
26291507 2015
33
Eosinophilic Gastritis Presenting as Tissue Necrosis. 61
26668805 2015
34
Eosinophilic Esophagitis and Gastroenteritis. 61
26233430 2015
35
Elements Involved In Promoting Eosinophilic Gastrointestinal Disorders. 61
27840774 2015
36
Spontaneous and transgenic rodent models of inflammatory bowel disease. 61
26155200 2015
37
A man with unsuspected marine eosinophilic gastritis. 61
25467651 2015
38
Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. 61
25234644 2014
39
Eosinophilic gastritis in children: clinicopathological correlation, disease course, and response to therapy. 61
24957155 2014
40
Eosinophilic gastritis with gastric outlet obstruction mimicking infantile hypertrophic pyloric stenosis. 61
25222812 2014
41
Rare association of IgA nephropathy with nephrotic syndrome in a patient with eosinophilic gastritis. 61
24969211 2014
42
A childhood case of eosinophilic gastritis and protein-losing enteropathy. 61
24351503 2014
43
The Churg-Strauss syndrome: diagnosed for the first time in a gastrectomy specimen. 61
23303591 2013
44
Gastric pneumatosis with associated eosinophilic gastritis in four black and white ruffed lemurs (Varecia variegata variegata). 61
23505706 2013
45
Selective IgA deficiency mimicking Churg-Strauss syndrome and hypereosinophilic syndrome: a case report. 61
23544278 2013
46
Contact allergic gastritis: an underdiagnosed entity? 61
23192576 2012
47
Case of Cronkhite Canada syndrome shows improvement with enteral supplements. 61
23029747 2012
48
Snakeskin-like pattern mimicking portal hypertensive gastropathy in patient with eosinophilic gastritis. 61
22211417 2012
49
Usefulness of single-balloon enteroscopy in pediatric Crohn's disease. 61
21855873 2012
50
Resolution of eosinophilic gastroenteritis after resection of uterine leiomyomas. 61
22009412 2011

Variations for Eosinophilic Gastritis

Expression for Eosinophilic Gastritis

Search GEO for disease gene expression data for Eosinophilic Gastritis.

Pathways for Eosinophilic Gastritis

Pathways related to Eosinophilic Gastritis according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.51 IL5 IL13 CDH26 CCR3 CCL26 CCL24
2
Show member pathways
13.1 IL5 IL13 CCR3 CCL26 CCL24 CCL11
3
Show member pathways
12.98 IL5 IL13 CCR3 CCL26 CCL24 CCL11
4
Show member pathways
12.57 IL5 IL13 EPX CCL11
5
Show member pathways
11.97 CCR3 CCL26 CCL24 CCL11
6
Show member pathways
11.89 CCR3 CCL26 CCL24 CCL11
7 11.7 SIGLEC8 IL5 CCR3
8 11.34 IL5 CCL26 CCL11
9 11.11 IL13 CCL26 CCL24 CCL11
10 11.05 IL5 IL13
11 11 IL5 IL13
12 10.99 IL5 IL13 CCL11
13 10.93 IL5 IL13
14 10.72 IL5 IL13 CCR3 CCL11
15 10.71 IL5 IL13 CCL26 CCL24 CCL11

GO Terms for Eosinophilic Gastritis

Cellular components related to Eosinophilic Gastritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 RNASE2 IL5 IL13 EPX CCL26 CCL24
2 extracellular space GO:0005615 9.17 IL5 IL13 EPX CCL26 CCL24 CCL11

Biological processes related to Eosinophilic Gastritis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.8 IL5 IL13 CCR3 CCL26 CCL24 CCL11
2 positive regulation of angiogenesis GO:0045766 9.75 CCR3 CCL24 CCL11
3 cellular response to tumor necrosis factor GO:0071356 9.73 CCL26 CCL24 CCL11
4 cellular response to interferon-gamma GO:0071346 9.67 CCL26 CCL24 CCL11
5 neutrophil chemotaxis GO:0030593 9.65 CCL26 CCL24 CCL11
6 cellular response to interleukin-1 GO:0071347 9.63 CCL26 CCL24 CCL11
7 positive regulation of actin filament polymerization GO:0030838 9.61 CCL26 CCL24 CCL11
8 monocyte chemotaxis GO:0002548 9.58 CCL26 CCL24 CCL11
9 eosinophil chemotaxis GO:0048245 9.57 CCL24 CCL11
10 chemokine-mediated signaling pathway GO:0070098 9.56 CCR3 CCL26 CCL24 CCL11
11 cellular sodium ion homeostasis GO:0006883 9.55 ATP4A ATP12A
12 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.54 ATP4A ATP12A
13 lymphocyte chemotaxis GO:0048247 9.54 CCL26 CCL24 CCL11
14 sodium ion export across plasma membrane GO:0036376 9.52 ATP4A ATP12A
15 cellular potassium ion homeostasis GO:0030007 9.51 ATP4A ATP12A
16 positive regulation of endothelial cell proliferation GO:0001938 9.46 CCR3 CCL26 CCL24 CCL11
17 inflammatory response GO:0006954 9.43 IL5 IL13 CCR3 CCL26 CCL24 CCL11
18 chemotaxis GO:0006935 9.02 RNASE2 CCR3 CCL26 CCL24 CCL11

Molecular functions related to Eosinophilic Gastritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.54 CCL26 CCL24 CCL11
2 sodium:potassium-exchanging ATPase activity GO:0005391 9.43 ATP4A ATP12A
3 receptor ligand activity GO:0048018 9.43 CCL26 CCL24 CCL11
4 potassium-transporting ATPase activity GO:0008556 9.4 ATP4A ATP12A
5 cytokine activity GO:0005125 9.35 IL5 IL13 CCL26 CCL24 CCL11
6 CCR chemokine receptor binding GO:0048020 9.33 CCL26 CCL24 CCL11
7 potassium:proton exchanging ATPase activity GO:0008900 9.32 ATP4A ATP12A
8 CCR3 chemokine receptor binding GO:0031728 8.8 CCL26 CCL24 CCL11

Sources for Eosinophilic Gastritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....